造血干细胞的同种异体移植仍然是某些血液系统恶性肿瘤的唯一治疗方法。这种治疗可能会产生许多副作用，导致多种相互依赖的身体和心理缺陷，影响患者的生活质量和社会参与，并且可能会成为一种障碍，有时会在移植后持续数年。几年来，移植后康复途径的整合已变得更加广泛，并且正在研究在越来越早的阶段提供多学科护理的举措。这种早期管理的目的是改善患者在移植前、移植期间和移植后的整体功能状态，以限制治疗的影响并确保尽快恢复尽可能满意的生活。国际文献和在法语世界进行的实验描述了异质的实践。根据这些文献和经验，本研究的目的是为良好的临床实践提出统一的建议，并确定造血干细胞移植前、移植中和移植后康复的进一步研究领域。版权所有 © 2024 Société癌症法语。由 Elsevier Masson SAS 出版。版权所有。

Allogeneic transplantation of haematopoietic stem cells is still the only curative treatment for certain haematological malignancies. This treatment can be responsible for a number of side-effects, leading to multiple and interdependent physical and psychological deficiencies that affect patients' quality of life and social participation, and can be experienced as a handicap, sometimes for several years after the transplant. For several years now, the integration of post-transplant rehabilitation pathways has been becoming more widespread, and initiatives to provide multidisciplinary care at an increasingly early stage are being studied. The aim of this early management is to improve the patient's overall functional state before, during and after the transplant, in order to limit the impact of the treatment and ensure the quickest possible return to a life that is as satisfying as possible. The international literature and the experiments carried out throughout the French-speaking world describe heterogeneous practices. Based on this literature and experience, the aim of this study is to issue homogenous recommendations for good clinical practice and to identify areas for further research into pre-transplant, per-transplant and post-transplant rehabilitation of haematopoietic stem cells.Copyright © 2024 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.